China Railway Materials Co (中國鐵路物資), a state-owned logistics firm and steel supplier, aims to raise as much as 6 billion yuan (US$943 million) selling shares in Shanghai to fund expansion.
The Beijing-based company will probably sell no more than 2.77 billion shares in Shanghai, according to a prospectus posted on the China Securities Regulatory Commission’s Web site. It may also offer as many as 1.44 billion shares in Hong Kong, including any over-allotment, the company said.
Proceeds from the Shanghai sale will go mainly to expand the company’s domestic logistic bases and operating networks and to replenish working capital. Funds raised in the Hong Kong offering, which is subject to regulatory approval, market conditions and investor confidence, will be used to set up overseas outlets, repay bank loans and boost capital, according to the prospectus.
Selling shares may be a challenge in a market where investor appetite has weakened amid Europe’s debt crisis and China’s economic slowdown. Initial public offerings on the Shanghai and Shenzhen bourses in the first half of the year raised 77.5 billion yuan, PriceWaterhouseCoopers said this month. That compares with 286.1 billion yuan in all of last year, the auditing firm said, which forecast 200 to 250 billion yuan worth of China Railway share sales this year.
China Railway Materials highlighted risks, including uncertainties about investment in China’s railway industry, slowing demand for steel and competition, according to the prospectus. The company boosted profit 47 percent to 1 billion yuan on revenue of 207 billion yuan last year, according to the prospectus.
NOTABLE SHIFT: By 2030, 50% of all laptops would be assembled in Southeast Asia, while Taiwan would still mostly focus on research and development, a report said Global laptop and desktop computer supply chains are expected to shift significantly away from China in the next 10 years, a Market Intelligence & Consulting Institute (MIC, 產業情報研究所) report said. By 2030, only 40 percent of global laptop production would remain in China, said the report, which was released on Thursday. “The reshuffling of the global supply chain will be one of the most important trends in the next 10 years,” the institute said in the report. “In the long run, key component makers will follow laptop assemblers in moving out of China.” The Taipei-based institute predicted most key component makers
Yageo Corp (國巨), the world’s third-largest supplier of multilayer ceramic capacitors, has formed a strategic alliance with Hon Hai Precision Industry Co (鴻海精密) to develop key electronic components for electric vehicles and digital healthcare, it said yesterday. The alliance is to help Yageo boost its revenue from high-end components for vehicles and industrial, medical and aerospace devices, as well as those used in 5G and Internet-of-Things devices, the company said. The companies signed the strategic alliance agreement at Yageo’s headquarters in New Taipei City’s Sindian District (新店). Their cooperation is to start this quarter, the companies said in a joint statement. “Through the cooperation
SUPPLY CONSTRAINTS: The transferred orders might not provide an immediate revenue boost given local chipmakers’ high utilization rates, a senior analyst said Shares of local contract chipmakers yesterday rose as much as the 10 percent daily limit, as investors bet on orders being transferred from Semiconductor Manufacturing International Corp (SMIC, 中芯國際) after the US imposed export restrictions on the Chinese chipmaker. United Microelectronics Corp (UMC, 聯電) shares soared 10 percent to close at NT$27.5 as 380 million shares changed hands on the Taiwan Stock Exchange. UMC is the world’s No. 3 foundry by revenue, followed by SMIC, according to data from market researcher TrendForce Corp (集邦科技). UMC has product and customer portfolios similar to those of SMIC, TrendForce said, adding that UMC offers 14-nanometer and
‘IMPORTANT MILESTONE’: The firm expects to launch the generic of Revlimid in the US after March 2022. It has already launched the product in some European countries Lotus Pharmaceutical Co Ltd (美時化學製藥) has received tentative approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for lenalidomide, the company said in a statement on Friday. The ANDA approval is for 2.5mg, 5mg, 10mg, 20mg and 25mg capsules of lenalidomide, which is a generic version of blood cancer drug Revlimid developed by Celgene Corp. It is the first product fully developed and manufactured in Lotus’ facilities in Taiwan. Lotus expects to launch the product in the US — based on its patent litigation settlement with Celgene last year — some time after March